Therapix Biosciences has entered into an agreement with the Hebrew University’s technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university’s Institute of Drug Research, the company said. The news comes one week after the company, which is developing cannabinoids for the treatment of Tourette Syndrome and for cognitive impairment, licensed a sublingual formulation of THC.
Therapix CEO Elran Haber commented, “In the last month, we signed two memoranda of understandings that are highly significant to the company’s advancement and realization of its business strategy. Such formulations will allow us to expand our development possibilities and broaden the company’s technological capability set. We believe, that through the technology for the nasal administration of the drug, we will be able to improve the bioavailability and efficacy, while shortening the reaction time and enhancing the safety profile of the active ingredient THC for treatment of the indications on which the company is focused.”
Read the Therapix press release.
